| Summary: | Because of the changing landscape of cardiac troponin (cTn) tests there is a need to independently compare the performance of the various assays (hs-cTnT with cTnT, cTnI, and hs-cTnI) and to determine the comparative clinical and economic impact of using these tests. A recent Rapid Response review of hs-cTnT by CADTH revealed that there is a lack of information on the economic impact of cTn tests. Given the gap in economic information and the need for good quality guidance on the use of cTn tests, a full health technology assessment (HTA) along with optimal use recommendations will inform the purchasing and clinical use of the most appropriate cTn assay, depending on the individual institutional context and provide guidance for clinicians in institutions electing to use hs-cTnT or hs-cTnI to reduce the impact of the lower specificity of these new assays. To gain efficiencies, the clinical evaluation component of the HTA will be built on the recent CADTH rapid review. This HTA project will evaluate the clinical and cost-effectiveness of high-sensitivity cardiac troponin T (hs-cTnT) and high-sensitivity cardiac troponin I (hs-cTnI) for the early diagnosis of acute coronary syndrome (ACS) in the emergency department (ED)
|
|---|